Korean aesthetic device company reported on Wednesday the receipt of the US Food and Drug Administration's 510 (K) clearance to market WONTECH SANDRO DUAL laser device across the global markets, including the US and Europe.
Recently, the SANDRO DUAL was launched in Korea Nd:YAG & Alexandrite based lasers mounted on one device.
According to the company, the SANDRO DUAL can be implemented in the hybrid mode in a short time difference between two wavelengths of 755nm and 1064nm. The energy is accurately delivered to a specific area to deliver an effective and quick treatment in hair removal as well as whitening without damaging surrounding tissue.
In addition, the the SANDRO DUAL's SCS (Skin Cooling Spray) cooling system minimizes patient discomfort from pain, swelling and redness.
EMA issues positive CHMP opinion for Revolution Medicines' RASONQUE in metastatic pancreatic cancer
Edesa Biotech receives FDA clearance to expand EB06 vitiligo study into the US
LTR Pharma launches Roxus nasal spray for ED in the US
Genezen agrees manufacturing collaboration with Galibra Neuroscience
FDA grants Breakthrough Therapy Designation to Legacy Healthcare's CINAINU (LH-8)
FDA approves Vantis Vascular's 6F CrossFAST model
Blue Lake Biotechnology reports interim data from Phase 1/2a paediatric clinical trial of BLB201
ArkBio reports FDA clearance of IND application for AK0406
Agilent to acquire Proscia for up to USD270m to expand digital pathology capabilities
Bristol Myers Squibb reports positive Phase 3 results for RYZ101 in neuroendocrine tumours
US WorldMeds awarded 2026 Vision of Hope Award
Urolution Medical secures FDA clearance for OpenFlo urinary catheter
Natera secures FDA Breakthrough Device designation for multi-cancer early detection assay
Medincell partner Teva secures FDA approval for monthly schizophrenia treatment
FDA approves Genentech's Tecentriq combination therapy for stage III colon cancer